I need help ASAP Please. It`s urgent... Thump up vote for the right answer with explaination.
What was johnson and johnson (Pharmaceutical company)`s largest future deductible amount that resulted in the deferred tax asset of $9902?
Financial Data are included in the link below.
https://fintel.io/doc/sec/200406/000020040618000005/form10-k20171231.htm
The 2017 effective tax rate increased by 76.1% as compared to 2016, primarily driven by the enactment of the TCIA in the United States in December 2017 The enactment of the TCJA resulted in a provisional tax charge in the fourth quarter of 2017, of approximately $13.0 billion or approximately 73.3 percentage point increase to the effective tax rate. The remainder of the increase in the tax rate for 2017 was related to the remeasurement of the Company's deferred tax assets in Belgium, as a result of changes in the Belgian statutory corporate tax rate enacted in December 2017, offset by a tax benefit for the closure of the Company's Animas insulin pump business The decrease in the 2016 effective tax rate, as compared to 2015 was primarily attributable to the Company adopting a new accounting standard for the reporting of additional tax benefits on share-based compensation that vested or were exercised during the fiscal year. The remainder of the change in the effective tax rate was primarily related to the lower earnings before taxes in the United States and the settlement of several uncertain tax positions in 2016 versus 2015 The decrease in the 2015 effective tax rate, as compared to 2014 was primarily attributable to the increases in taxable income in lower tax jurisdictions relative to higher tax jurisdictions and a tax benefit resulting from a restructuring of international affiliates. The items noted above reflect the key drivers of the rate reconciliation Temporary differences and carryforwards for 2017 and 2016 were as follows: 2017 Deferred Tax 2016 Deferred Tax Asset Liabilitv Asset Liability (Dollars in Millions) Employee related obligations Stock based compensation 2,259 507 2,958 749 (6,672) Non-deductible intangibles International R&D capitalized for tax Reserves & liabilities (6,506) 1,264 1,857 1,309 1,307 1,718 1,316 762 1,101 755 e reported for tax purposes Net operating loss carryforward international Undistributed foreign earnings Miscellaneous international Miscellaneous U.S Total deferred income taxes (4,457) (194) 1,135 9,902 (11.166) 10,144 (6,906) The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will realize future taxable income sufficient to utilize these deferred tax assets. The following table summarizes the activity related to unrecognized tax benefits
